View ValuationODI Pharma 将来の成長Future 基準チェック /06現在、 ODI Pharmaの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長23.6%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報お知らせ • May 03ODI Pharma AB Provides Sales Guidance for the Third Quarter of the Year 2024ODI Pharma AB provided sales guidance for the third quarter of the year 2024. For the quarter, the company's sales are expected to exceed SEK 13.5 million. This increase in revenue largely results from their successful partnership with Synoptis Pharma, which has led to several product shipments.すべての更新を表示Recent updatesBoard Change • May 21Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. CEO & Director Jan-Mark Edewaard was the last director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Aug 29+ 3 more updatesODI Pharma AB (publ) to Report First Half, 2026 Results on Feb 26, 2026ODI Pharma AB (publ) announced that they will report first half, 2026 results on Feb 26, 2026お知らせ • Jul 29ODI Pharma AB (publ) to Report Fiscal Year 2025 Results on Aug 28, 2025ODI Pharma AB (publ) announced that they will report fiscal year 2025 results on Aug 28, 2025お知らせ • Jan 29ODI Pharma AB (publ) to Report Q2, 2025 Results on Feb 27, 2025ODI Pharma AB (publ) announced that they will report Q2, 2025 results on Feb 27, 2025お知らせ • Dec 30ODI Pharma AB (publ) Appoints Jan-Mark Edewaard as Board MemberODI Pharma AB (publ) announced that at the AGM held on December 30, 2024, approved the appointment of Jan-Mark Edewaard as board member.お知らせ • Dec 12ODI Pharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 2.238009 million.ODI Pharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 2.238009 million. Security Name: Shares Security Type: Common Stock Securities Offered: 695,034 Price\Range: SEK 3.22 Transaction Features: Rights Offeringお知らせ • Oct 30ODI Pharma AB (publ) to Report Q1, 2025 Results on Nov 22, 2024ODI Pharma AB (publ) announced that they will report Q1, 2025 results on Nov 22, 2024Reported Earnings • Aug 30Full year 2024 earnings released: EPS: kr0.023 (vs kr0.45 loss in FY 2023)Full year 2024 results: EPS: kr0.023 (up from kr0.45 loss in FY 2023). Revenue: kr25.4m (up kr25.3m from FY 2023). Net income: kr356.0k (up kr7.26m from FY 2023). Profit margin: 1.4% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.お知らせ • Jul 31ODI Pharma AB (publ) to Report Fiscal Year 2024 Results on Aug 29, 2024ODI Pharma AB (publ) announced that they will report fiscal year 2024 results on Aug 29, 2024Reported Earnings • Jun 04Third quarter 2024 earnings released: EPS: kr0.085 (vs kr0.062 loss in 3Q 2023)Third quarter 2024 results: EPS: kr0.085 (up from kr0.062 loss in 3Q 2023). Revenue: kr13.9m (up kr13.9m from 3Q 2023). Net income: kr1.30m (up kr2.24m from 3Q 2023). Profit margin: 9.3% (up from net loss in 3Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.お知らせ • May 03ODI Pharma AB Provides Sales Guidance for the Third Quarter of the Year 2024ODI Pharma AB provided sales guidance for the third quarter of the year 2024. For the quarter, the company's sales are expected to exceed SEK 13.5 million. This increase in revenue largely results from their successful partnership with Synoptis Pharma, which has led to several product shipments.お知らせ • May 01ODI Pharma AB (publ) to Report Q3, 2024 Results on May 30, 2024ODI Pharma AB (publ) announced that they will report Q3, 2024 results on May 30, 2024Reported Earnings • Feb 25Second quarter 2024 earnings released: EPS: kr0.062 (vs kr0.11 loss in 2Q 2023)Second quarter 2024 results: EPS: kr0.062 (up from kr0.11 loss in 2Q 2023). Revenue: kr2.95m (up kr2.88m from 2Q 2023). Net income: kr946.5k (up kr2.68m from 2Q 2023). Profit margin: 32% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue.お知らせ • Jan 24ODI Pharma AB (publ) to Report Q2, 2024 Results on Feb 22, 2024ODI Pharma AB (publ) announced that they will report Q2, 2024 results on Feb 22, 2024Reported Earnings • Nov 26First quarter 2024 earnings released: kr0.095 loss per share (vs kr0.10 loss in 1Q 2023)First quarter 2024 results: kr0.095 loss per share (improved from kr0.10 loss in 1Q 2023). Revenue: kr534.3k (up kr506.3k from 1Q 2023). Net loss: kr1.44m (loss narrowed 10.0% from 1Q 2023).お知らせ • Nov 24ODI Pharma AB (publ) to Report Fiscal Year 2023 Results on Nov 24, 2023ODI Pharma AB (publ) announced that they will report fiscal year 2023 results on Nov 24, 2023お知らせ • Nov 14ODI Pharma AB (publ), Annual General Meeting, Dec 15, 2023ODI Pharma AB (publ), Annual General Meeting, Dec 15, 2023, at 10:30 Central European Standard Time. Location: In the office of the company at Östermalmstorg 1, 114 42 Stockholm Stockholm Sweden Agenda: To consider the presentation of the annual report and auditor's report; to consider the adoption of the income statement and the balance sheet; to consider allocation of the company's result according to the adopted balance sheet; to consider discharge from liability for board members and the managing director; to consider determination of the number of members in the board of directors, alternate members, and the number of auditors and alternate auditors; to consider the election of the Board of Directors and accounting firm or auditors; and to consider other matters.お知らせ • Oct 25ODI Pharma AB (publ) to Report Q1, 2024 Results on Nov 23, 2023ODI Pharma AB (publ) announced that they will report Q1, 2024 results on Nov 23, 2023Reported Earnings • Aug 27Full year 2023 earnings released: kr0.41 loss per share (vs kr0.48 loss in FY 2022)Full year 2023 results: kr0.41 loss per share (improved from kr0.48 loss in FY 2022). Net loss: kr6.16m (loss narrowed 15% from FY 2022).お知らせ • Jul 26ODI Pharma AB (publ) to Report Fiscal Year 2023 Results on Aug 24, 2023ODI Pharma AB (publ) announced that they will report fiscal year 2023 results on Aug 24, 2023お知らせ • Jan 25+ 1 more updateODI Pharma Receives Approval from the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in Poland to Distribute and Sell Its Products on the Polish MarketODI Pharma AB announces that the Company has received approval from the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL)in Polandfor its Marketing Authorization Holder (MAH) application. The approval means that ODI has the right to distribute and sell its medical cannabis products on the Polish market. The approved Marketing Authorization Holder application is an important milestone and has meant 3 years of intensive work for the Company as it is required to proceed with the work to start selling the products on the Polish medical market. The Company will now proceed with the necessary steps to bring the products to the Polish market as soon as possible, through its subsidiary ODI Pharma Polska Sp. z o.o.お知らせ • Nov 17ODI Pharma AB (publ), Annual General Meeting, Dec 16, 2022ODI Pharma AB (publ), Annual General Meeting, Dec 16, 2022.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、ODI Pharma は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測DB:6OD - アナリストの将来予測と過去の財務データ ( )SEK Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202520-1-1-1N/A9/30/20259-5-4-4N/A6/30/20253-6-3-3N/A3/31/202510-6-6-6N/A12/31/202422-4-3-3N/A9/30/202422-100N/A6/30/202422-1-4-4N/A3/31/202415-2-1-1N/A12/31/20231-4-3-3N/A9/30/20231-7-5-5N/A6/30/20230-7-5-5N/A3/31/20230-7-5-5N/A12/31/20220-8-6-6N/A9/30/20220-8-7-7N/A6/30/20220-7-7-7N/A3/31/20221-7-7-7N/A12/31/20210-5-7-7N/A9/30/2021N/A-4-6-6N/A6/30/2021N/A-4-6-6N/A3/31/20210-3-7-7N/A12/31/20200-5-6-6N/A9/30/20200-6-7-7N/A6/30/2020N/A-5-5-5N/A3/31/20200-5-5-5N/A12/31/20190-3-3-3N/A9/30/20190-3N/A-3N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 6ODの予測収益成長が 貯蓄率 ( 1.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 6ODの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 6ODの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 6ODの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 6ODの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 6ODの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 11:59終値2026/05/25 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋ODI Pharma AB (publ) 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 03ODI Pharma AB Provides Sales Guidance for the Third Quarter of the Year 2024ODI Pharma AB provided sales guidance for the third quarter of the year 2024. For the quarter, the company's sales are expected to exceed SEK 13.5 million. This increase in revenue largely results from their successful partnership with Synoptis Pharma, which has led to several product shipments.
Board Change • May 21Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. CEO & Director Jan-Mark Edewaard was the last director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Aug 29+ 3 more updatesODI Pharma AB (publ) to Report First Half, 2026 Results on Feb 26, 2026ODI Pharma AB (publ) announced that they will report first half, 2026 results on Feb 26, 2026
お知らせ • Jul 29ODI Pharma AB (publ) to Report Fiscal Year 2025 Results on Aug 28, 2025ODI Pharma AB (publ) announced that they will report fiscal year 2025 results on Aug 28, 2025
お知らせ • Jan 29ODI Pharma AB (publ) to Report Q2, 2025 Results on Feb 27, 2025ODI Pharma AB (publ) announced that they will report Q2, 2025 results on Feb 27, 2025
お知らせ • Dec 30ODI Pharma AB (publ) Appoints Jan-Mark Edewaard as Board MemberODI Pharma AB (publ) announced that at the AGM held on December 30, 2024, approved the appointment of Jan-Mark Edewaard as board member.
お知らせ • Dec 12ODI Pharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 2.238009 million.ODI Pharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 2.238009 million. Security Name: Shares Security Type: Common Stock Securities Offered: 695,034 Price\Range: SEK 3.22 Transaction Features: Rights Offering
お知らせ • Oct 30ODI Pharma AB (publ) to Report Q1, 2025 Results on Nov 22, 2024ODI Pharma AB (publ) announced that they will report Q1, 2025 results on Nov 22, 2024
Reported Earnings • Aug 30Full year 2024 earnings released: EPS: kr0.023 (vs kr0.45 loss in FY 2023)Full year 2024 results: EPS: kr0.023 (up from kr0.45 loss in FY 2023). Revenue: kr25.4m (up kr25.3m from FY 2023). Net income: kr356.0k (up kr7.26m from FY 2023). Profit margin: 1.4% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
お知らせ • Jul 31ODI Pharma AB (publ) to Report Fiscal Year 2024 Results on Aug 29, 2024ODI Pharma AB (publ) announced that they will report fiscal year 2024 results on Aug 29, 2024
Reported Earnings • Jun 04Third quarter 2024 earnings released: EPS: kr0.085 (vs kr0.062 loss in 3Q 2023)Third quarter 2024 results: EPS: kr0.085 (up from kr0.062 loss in 3Q 2023). Revenue: kr13.9m (up kr13.9m from 3Q 2023). Net income: kr1.30m (up kr2.24m from 3Q 2023). Profit margin: 9.3% (up from net loss in 3Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.
お知らせ • May 03ODI Pharma AB Provides Sales Guidance for the Third Quarter of the Year 2024ODI Pharma AB provided sales guidance for the third quarter of the year 2024. For the quarter, the company's sales are expected to exceed SEK 13.5 million. This increase in revenue largely results from their successful partnership with Synoptis Pharma, which has led to several product shipments.
お知らせ • May 01ODI Pharma AB (publ) to Report Q3, 2024 Results on May 30, 2024ODI Pharma AB (publ) announced that they will report Q3, 2024 results on May 30, 2024
Reported Earnings • Feb 25Second quarter 2024 earnings released: EPS: kr0.062 (vs kr0.11 loss in 2Q 2023)Second quarter 2024 results: EPS: kr0.062 (up from kr0.11 loss in 2Q 2023). Revenue: kr2.95m (up kr2.88m from 2Q 2023). Net income: kr946.5k (up kr2.68m from 2Q 2023). Profit margin: 32% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue.
お知らせ • Jan 24ODI Pharma AB (publ) to Report Q2, 2024 Results on Feb 22, 2024ODI Pharma AB (publ) announced that they will report Q2, 2024 results on Feb 22, 2024
Reported Earnings • Nov 26First quarter 2024 earnings released: kr0.095 loss per share (vs kr0.10 loss in 1Q 2023)First quarter 2024 results: kr0.095 loss per share (improved from kr0.10 loss in 1Q 2023). Revenue: kr534.3k (up kr506.3k from 1Q 2023). Net loss: kr1.44m (loss narrowed 10.0% from 1Q 2023).
お知らせ • Nov 24ODI Pharma AB (publ) to Report Fiscal Year 2023 Results on Nov 24, 2023ODI Pharma AB (publ) announced that they will report fiscal year 2023 results on Nov 24, 2023
お知らせ • Nov 14ODI Pharma AB (publ), Annual General Meeting, Dec 15, 2023ODI Pharma AB (publ), Annual General Meeting, Dec 15, 2023, at 10:30 Central European Standard Time. Location: In the office of the company at Östermalmstorg 1, 114 42 Stockholm Stockholm Sweden Agenda: To consider the presentation of the annual report and auditor's report; to consider the adoption of the income statement and the balance sheet; to consider allocation of the company's result according to the adopted balance sheet; to consider discharge from liability for board members and the managing director; to consider determination of the number of members in the board of directors, alternate members, and the number of auditors and alternate auditors; to consider the election of the Board of Directors and accounting firm or auditors; and to consider other matters.
お知らせ • Oct 25ODI Pharma AB (publ) to Report Q1, 2024 Results on Nov 23, 2023ODI Pharma AB (publ) announced that they will report Q1, 2024 results on Nov 23, 2023
Reported Earnings • Aug 27Full year 2023 earnings released: kr0.41 loss per share (vs kr0.48 loss in FY 2022)Full year 2023 results: kr0.41 loss per share (improved from kr0.48 loss in FY 2022). Net loss: kr6.16m (loss narrowed 15% from FY 2022).
お知らせ • Jul 26ODI Pharma AB (publ) to Report Fiscal Year 2023 Results on Aug 24, 2023ODI Pharma AB (publ) announced that they will report fiscal year 2023 results on Aug 24, 2023
お知らせ • Jan 25+ 1 more updateODI Pharma Receives Approval from the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in Poland to Distribute and Sell Its Products on the Polish MarketODI Pharma AB announces that the Company has received approval from the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL)in Polandfor its Marketing Authorization Holder (MAH) application. The approval means that ODI has the right to distribute and sell its medical cannabis products on the Polish market. The approved Marketing Authorization Holder application is an important milestone and has meant 3 years of intensive work for the Company as it is required to proceed with the work to start selling the products on the Polish medical market. The Company will now proceed with the necessary steps to bring the products to the Polish market as soon as possible, through its subsidiary ODI Pharma Polska Sp. z o.o.
お知らせ • Nov 17ODI Pharma AB (publ), Annual General Meeting, Dec 16, 2022ODI Pharma AB (publ), Annual General Meeting, Dec 16, 2022.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.